Clinical Trial Update: Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study [Phase 2]

View source ↗

Summary

Phase 2 trial update on trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer (TRAIN study) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Breast Cancer, HER2 Positive | Phase 2 | Status: COMPLETED